AZN - Astrazeneca plc Stock Analysis
Astrazeneca plc (AZN) is a publicly traded company listed on the NYSE. It operates in the Drug Manufacturers - General industry, part of the broader Healthcare sector. The company has a market capitalization of 317.47B, generates annual revenue of 58.74B, and reports net income of 10.22B. As of the latest data, the stock is trading at 204.76 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is moderately valued and aligns with market expectations for established companies. The PEG ratio is within a normal range, suggesting the stock is fairly priced for its expected growth. The company maintains a healthy balance between debt and equity, which is typical for stable businesses. The stock offers a moderate dividend yield (1.67%), which may appeal to income-focused investors. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Buy (4.15), indicating current market sentiment. Institutional ownership is reported at 53.77%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 44.12%, trading within a 52-week range of 122.26 - 195.90.
AZN - Astrazeneca plc
204.76
Analyst Consensus
Buy 4.15
AZN – Analyst Rating Summary
- Strong Buy: 11
- Buy: 18
- Hold: 4
- Sell: 1
- Strong Sell: 0
- Total Analysts: 34
| Index: | - | P/E: | 31.26 | EPS (ttm): | 6.55 | Insider Own: | 4.81% | Shs Outstand: | 1.55B | Perf Week: | 9.23% |
| Market Cap: | 317.47B | Forward P/E: | 17.71 | EPS next Y: | 11.56 | Insider Trans: | 0.00% | Shs Float: | 1.48B | Perf Month: | 10.39% |
| Income(ttm): | 10.22B | PEG: | 1.48 | EPS next Q: | 2.50 | Inst Own: | 53.77% | Short Float: | 0.26% | Perf Quarter: | 17.07% |
| Revenue(ttm): | 58.74B | P/S: | 5.40 | EPS this Y: | 12.42% | Inst Trans: | -2.58% | Short Ratio: | 10.17 | Perf Half Y: | 38.09% |
| Book/sh: | 29.60 | P/B: | 6.92 | EPS next Y: | 12.30% | ROA: | 9.38% | Short Interest: | 3.88M | Perf Year: | 44.12% |
| Cash/sh: | 3.70 | P/C: | 55.30 | EPS next 5Y: | 11.96% | ROE: | 22.86% | 52W Range: | 122.26 - 195.90 | Perf YTD: | 16.67% |
| Dividend Est.: | 3.42 (1.67%) | P/FCF: | 26.11 | EPS past 3/5Y: | 45.90% 22.05% | ROIC: | 13.67% | 52W High: | 195.90 4.53% | Beta: | 0.39 |
| Dividend TTM: | 3.16 (1.54%) | Quick Ratio: | 0.72 | Sales past 3/5Y: | 9.82% 16.31% | Gross Margin: | 74.35% | 52W Low: | 122.26 67.48% | Perf 5Y: | 102.89% |
| Dividend Ex-Date: | Feb 20, 2026 | Current Ratio: | 0.94 | EPS Y/Y TTM: | 45.27% | Oper. Margin: | 23.16% | RSI (14): | 65.42 | Volatility: | 2.76% 3.07% |
| Employees: | 94300 | Debt/Eq: | 0.61 | Sales Y/Y TTM: | 8.63% | Profit Margin: | 17.41% | Recom: | 1.63 | Target Price: | 214.44 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.54 | EPS Q/Q: | 54.97% | Payout: | 47.19% | Rel Volume: | 9.07 | Prev Close: | 193.40 |
| Sales Surprise: | 0.38% | EPS Surprise: | 1.32% | Sales Q/Q: | 4.11% | Earnings: | Feb 10 BMO | Avg Volume: | 381.49K | Price: | 204.76 |
| SMA20: | 9.58% | SMA50: | 10.73% | SMA200: | 28.33% | Overbought: -4.73% | Volume: | 3,459,667 | Change: | 5.87% | |
Graham Classic formula value: 190.68
(P/E=8 * 1g) Min value: 117.4
(current P/E * 2g) Max value: 324.55
Average value: 210.88
About Astrazeneca plc
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.